This site is intended for health professionals only

New data on Bayer’s oral anticoagulant Xarelto®



Bayer HealthCare has announced that new data presentations on its novel oral anticoagulant Xarelto® (rivaroxaban) to be presented at the American Heart Association (AHA) Scientific Sessions 2013 in Dallas, TX, USA, November 16-20, 2013, will provide further insights for physicians and patients on the clinical benefit of rivaroxaban for stroke prevention in patients with non-valvular atrial fibrillation (AF).
AF is a common heart rhythm disorder which elevates the risk of stroke by 500%, causes disability in more than half of patients and is associated with a 50% likelihood of death within one year.
Notable data analyses on Bayer’s rivaroxaban to be presented at AHA Scientific Sessions 2013 include*:
Rivaroxaban Oral and Poster Presentations on Stroke Prevention in AF
  • Management of Major Bleeding Events in Patients Treated with Rivaroxaban vs Warfarin: Results from the ROCKET AF Trial
– Oral Presentation: AOS.405.01-Dilemmas in the Anticoagulation of Atrial Fibrillation; Presentation: 15879
– Tuesday, November 19, 2013; 09:00-09:15; Hall B-1
  • Real-World Comparative Effectiveness and Safety of Rivaroxaban and Warfarin in Non-Valvular Atrial Fibrillation Patients
– Oral Presentation: AOS.213.01-Atrial Fibrillation, Stroke and Anticoagulant Strategies: Real-World Delivery of Care and Outcomes; Presentation: 15875
– Tuesday, November 19, 2013; 11:30-11:45; Room D162
  • Hospital Length of Stay: Does Rivaroxaban Reduce Inpatient Stay Compared to Warfarin among Patients with Non-Valvular Atrial Fibrillation?
– Oral Presentation: AOS.213.01-Atrial Fibrillation, Stroke and Anticoagulant Strategies: Real-World Delivery of Care and Outcomes; Presentation: 15884
– Tuesday, November 19, 2013; 11:45-12:00; Room D162
  • Patterns of International Normalized Ratio Stability among Newly Initiated Warfarin Patients with Non-Valvular Atrial Fibrillation
– Poster Session: APS.213.04-Medical Management: Atrial Fibrillation and Hypertension, Anticoagulants and Adherence; Poster Board: 2167 – Presentation: 15858
– Tuesday, November 19, 2013; 15.00-16:30; Hall F, Core 2
Full data from the pivotal Phase III ROCKET AF Study were presented at the AHA Scientific Sessions 2010 and were published in the New England Journal of Medicine (NEJM) in September 2011. Once-daily Xarelto has been approved for the prevention of stroke and systemic embolism in patients with non-valvular AF in more than 100 countries worldwide. Since the first approval of Xarelto in 2008 to prevent venous blood clots following major orthopaedic surgery, Xarelto has been used in millions of patients worldwide across its five approved indications.
GARFIELD-AF Registry Data to be Presented*
Independently, the Thrombosis Research Institute (TRI) will present new data from GARFIELD-AF, an observational, multicentre study of men and women with newly diagnosed AF with one or more additional investigator determined risk factors for stroke. The GARFIELD-AF Registry is an academic research initiative, led by the TRI and a multi-disciplinary Steering Committee and supported by an unrestricted educational grant from Bayer Pharma AG.

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine